Finance

Lists
Outlook: 32.5% bullish·12.5% bearish
Go to analysis
MRSH:NYSE
Marsh & McLennan Companies Inc
$191.26
+1.46%
(+2.76) 1D
$191.26
0.00% (0.00)
After hours
Closed: Oct 20, 4:01:12 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for MRSH...
Open
$190.58
High
$193.06
Low
$189.23
Mkt. cap
89.63B
Avg. vol.
2.85M
Volume
2.14M
52-wk high
$198.49
52-wk low
$156.60
Beta
0.59
Shares outstanding
475.51M
No. of employees
95K
Open
$190.58
High
$193.06
Low
$189.23
Mkt. cap
89.63B
Avg. vol.
2.85M
Volume
2.14M
52-wk high
$198.49
52-wk low
$156.60
Beta
0.59
Shares outstanding
475.51M
No. of employees
95K
News stories
From web sources and news partners
Profile
Marsh & McLennan Companies, Inc., trading as Marsh McLennan and Marsh, is an American professional services firm headquartered in New York City, with businesses in insurance brokerage, risk management, reinsurance services, talent management, investment advisory, and management consulting. Its four main operating companies are Marsh, which offers risk management, insurance broking, insurance program management, risk consulting, analytical modeling, and alternative risk financing services; Marsh Re, a reinsurance intermediary and advisor; Mercer, which provides consulting to employers for health insurance, retirement plans, and pension plans; and Oliver Wyman, including Lippincott and NERA Economic Consulting, which provides consulting services. In 2024, risk and insurance services contributed a total of 63% of revenues and 71% of operating profit, while consulting contributed 37% of revenues and 29% of operating profit. It is the largest insurance broker worldwide. The company is ranked 175th on the Fortune 500 and 267th on the Forbes Global 2000. Wikipedia
About Marsh & McLennan Companies Inc
CEOJohn Q. Doyle
Employees95K
Founded1905
HeadquartersNew York, New York, United States
SectorInsurance
Websitecorporate.marsh.com
Analyst ratings
Based on 16 analysts giving stock ratings to MRSH in the past 3 months
Hold
Buy
5
Hold
10
Sell
1
12-month forecast
Based on 16 Wall Street analysts offering 12 month price targets for MRSH in the last 3 months.
Highest
Current $191.26
$234.00 (+22.35%)
Average
$203.79 (+6.55%)
Lowest
$180.00 (-5.89%)
Analyst
Recommendation
Action
Price target
Projected
Date
Brian Meredith
UBS
Buy
Maintained
$222.00
+16.1%
10/20/2026
Pablo Singzon
J.P. Morgan
Buy
Reiterated
$218.00
+14%
10/20/2026
Yaron Kinar
Mizuho Securities
Hold
Maintained
$200.00
+4.6%
10/19/2026
Meyer Shields
KBW
Hold
Maintained
$201.00
+5.1%
10/19/2026
Robert Cox CFA
Goldman Sachs
Hold
Maintained
$199.00
+4%
10/15/2026
Bob Huang
Morgan Stanley
Hold
Reiterated
$190.00
-0.7%
10/16/2026
Rowland Mayor
RBC Capital
Hold
Maintained
$200.00
+4.6%
10/15/2026
Matthew Heimermann
Citi
Hold
Maintained
$203.00
+6.1%
10/16/2026
Alex Scott
Barclays
Buy
Maintained
$206.00
+7.7%
10/16/2026
Joshua Shanker
Bank of America Securities
Sell
Reiterated
$180.00
-5.9%
10/15/2026
Elyse Greenspan
Wells Fargo
Hold
Reiterated
$197.00
+3%
10/16/2026
Hans Engel
Erste Group
Buy
Initiated
-
-
09/08/2026
Michael Zaremski
BMO Capital
Hold
Maintained
$203.00
+6.1%
08/25/2026
Harry Fong
Roth MKM
Hold
Maintained
$200.00
+4.6%
07/22/2026
David Motemaden
Evercore ISI
Buy
Maintained
$234.00
+22.3%
07/22/2026
Adam Klauber
William Blair
Hold
Maintained
-
-
07/21/2026
Paul Newsome
Piper Sandler
Hold
Maintained
$182.00
-4.8%
07/15/2026
Ryan Tunis
Cantor Fitzgerald
Buy
Maintained
$218.00
+14%
07/09/2026
Jimmy Bhullar
J.P. Morgan
Buy
Reiterated
$226.00
+18.2%
03/05/2026
Gregory Peters
Raymond James
Buy
Upgraded
$225.00
+17.6%
02/17/2026
Last report
Oct 15, 2026
Fiscal period
Q3 2026
$2.03 / $1.97
+3.16%beat
Revenue / Est. (USD)
6.86B / 6.64B
+3.32%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
6.60B
7.60B
7.40B
6.86B
Cost of goods sold
3.78B
4.05B
4.09B
4.03B
Cost of revenue
3.78B
4.05B
4.09B
4.03B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
-
-
-
-
Operating expense
1.13B
1.70B
1.36B
1.57B
Total operating expenses
4.92B
5.75B
5.46B
5.60B
Operating income
1.68B
1.85B
1.95B
1.26B
Other non operating income
-
-
-
-
EBT including unusual items
1.06B
1.58B
1.70B
1.03B
EBT excluding unusual items
1.46B
1.63B
1.71B
1.03B
Income tax expense
222.00M
395.00M
411.00M
221.00M
Effective tax rate
21.02%
24.98%
24.15%
21.39%
Other operating expenses
1.13B
1.70B
1.36B
1.57B
Net income
821.00M
1.15B
1.27B
808.00M
Net profit margin
12.45%
15.08%
17.10%
11.77%
Earnings per share
2.12
3.29
2.96
2.03
Interest and investment income
21.00M
17.00M
8.00M
18.00M
Interest expense
-235.00M
-240.00M
-250.00M
-248.00M
Net interest expenses
-214.00M
-223.00M
-242.00M
-230.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
1.91B
2.08B
2.18B
1.49B
Gain or loss from assets sale
4.00M
-
-7.00M
-5.00M
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps